Jeff  Castelli net worth and biography

Jeff Castelli Biography and Net Worth

Dr. Castelli joined Amicus in July 2005 and currently serves as Chief Development Officer. He has over 20 years of experience in the Biotech and Orphan Drug industry, focused on rare disease research and development of medicines from discovery through market authorization. In his current capacity, he provides strategic leadership across all R&D activities, including direct oversight of Science, Clinical Research, and Medical Affairs. Previously at Amicus he has had responsibility for a number of different functions including program management, portfolio planning and the gene therapy business. Prior to joining Amicus, Dr. Castelli was a healthcare strategy consultant at Health Advances LLC and worked in business development at Neose Pharmaceuticals Inc. He received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania, and is an author on numerous publications and patents in the field of rare disease drug development.

What is Jeff Castelli's net worth?

The estimated net worth of Jeff Castelli is at least $3.45 million as of December 19th, 2023. Dr. Castelli owns 359,736 shares of Amicus Therapeutics stock worth more than $3,449,868 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Castelli may own. Additionally, Dr. Castelli receives an annual salary of $709,640.00 as Insider at Amicus Therapeutics. Learn More about Jeff Castelli's net worth.

How old is Jeff Castelli?

Dr. Castelli is currently 52 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. The oldest executive at Amicus Therapeutics is Mr. Simon Nicolas Reade Harford, Chief Financial Officer, who is 64 years old. Learn More on Jeff Castelli's age.

What is Jeff Castelli's salary?

As the Insider of Amicus Therapeutics, Inc., Dr. Castelli earns $709,640.00 per year. There are 2 executives that earn more than Dr. Castelli. The highest earning executive at Amicus Therapeutics is Mr. Bradley L. Campbell M.B.A., CEO, President & Director, who commands a salary of $984,090.00 per year. Learn More on Jeff Castelli's salary.

How do I contact Jeff Castelli?

The corporate mailing address for Dr. Castelli and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Jeff Castelli's contact information.

Has Jeff Castelli been buying or selling shares of Amicus Therapeutics?

Jeff Castelli has not been actively trading shares of Amicus Therapeutics during the last ninety days. Most recently, Jeff Castelli sold 17,500 shares of the business's stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $13.25, for a transaction totalling $231,875.00. Following the completion of the sale, the insider now directly owns 359,736 shares of the company's stock, valued at $4,766,502. Learn More on Jeff Castelli's trading history.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 350,095 shares worth more than $4,532,405.15. The most recent insider tranaction occured on November, 6th when CEO Bradley L Campbell sold 7,901 shares worth more than $98,762.50. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.

Information on this page was last updated on 11/6/2024.

Jeff Castelli Insider Trading History at Amicus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2023Sell17,500$13.25$231,875.00359,736View SEC Filing Icon  
6/22/2015Sell18,981$13.94$264,595.14View SEC Filing Icon  
6/15/2015Sell7,377$14.17$104,532.09View SEC Filing Icon  
6/8/2015Sell17,312$12.87$222,805.44View SEC Filing Icon  
5/11/2015Sell10,000$10.84$108,400.00View SEC Filing Icon  
4/1/2015Sell9,489$10.69$101,437.41View SEC Filing Icon  
1/5/2015Sell4,667$9.00$42,003.00View SEC Filing Icon  
11/25/2014Sell8,103$8.00$64,824.00View SEC Filing Icon  
10/3/2014Sell8,552$7.00$59,864.00View SEC Filing Icon  
See Full Table

Jeff Castelli Buying and Selling Activity at Amicus Therapeutics

This chart shows Jeff Castelli's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $9.59
Low: $9.38
High: $9.68

50 Day Range

MA: $10.89
Low: $9.52
High: $12.01

2 Week Range

Now: $9.59
Low: $9.02
High: $14.57

Volume

1,961,452 shs

Average Volume

2,723,220 shs

Market Capitalization

$2.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68